{
  "metadata": {
    "claims_file": "data/claims/Flublok_Claims.json",
    "documents": [
      "FlublokPI"
    ],
    "total_claims": 9,
    "started_at": "2025-07-28T17:40:56.399953",
    "completed_at": "2025-07-28T17:42:33.117205"
  },
  "claims": {
    "claim_000": {
      "claim_id": "claim_000",
      "claim": "Flublok ensures identical antigenic match with WHO- and FDA-selected flu strains.",
      "started_at": "2025-07-28T17:40:56.399996",
      "documents": {
        "FlublokPI": {
          "document": "FlublokPI",
          "agents_run": [
            {
              "agent": "supporting_evidence",
              "success": true,
              "timestamp": "2025-07-28T17:41:04.697029"
            }
          ],
          "final_judgment": null,
          "success": true
        }
      },
      "completed_at": "2025-07-28T17:41:04.697047"
    },
    "claim_001": {
      "claim_id": "claim_001",
      "claim": "Flublok contains 3x the hemagglutinin (HA) antigen content of standard-dose flu vaccines, which has been linked to greater immunogenicity vs standard-dose flu vaccines.",
      "started_at": "2025-07-28T17:41:04.697105",
      "documents": {
        "FlublokPI": {
          "document": "FlublokPI",
          "agents_run": [
            {
              "agent": "supporting_evidence",
              "success": true,
              "timestamp": "2025-07-28T17:41:20.078626"
            }
          ],
          "final_judgment": null,
          "success": true
        }
      },
      "completed_at": "2025-07-28T17:41:20.078640"
    },
    "claim_002": {
      "claim_id": "claim_002",
      "claim": "Cell- and egg-based flu vaccines have the potential to develop mutations during production, which may reduce their effectiveness.",
      "started_at": "2025-07-28T17:41:20.078694",
      "documents": {
        "FlublokPI": {
          "document": "FlublokPI",
          "agents_run": [
            {
              "agent": "supporting_evidence",
              "success": true,
              "timestamp": "2025-07-28T17:41:30.992436"
            }
          ],
          "final_judgment": null,
          "success": true
        }
      },
      "completed_at": "2025-07-28T17:41:30.992446"
    },
    "claim_003": {
      "claim_id": "claim_003",
      "claim": "Recombinant technology leads to a broader immune response that may provide cross-protection, even in a mismatch season.",
      "started_at": "2025-07-28T17:41:30.992493",
      "documents": {
        "FlublokPI": {
          "document": "FlublokPI",
          "agents_run": [
            {
              "agent": "supporting_evidence",
              "success": true,
              "timestamp": "2025-07-28T17:41:40.620035"
            }
          ],
          "final_judgment": null,
          "success": true
        }
      },
      "completed_at": "2025-07-28T17:41:40.620051"
    },
    "claim_004": {
      "claim_id": "claim_004",
      "claim": "Vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
      "started_at": "2025-07-28T17:41:40.620109",
      "documents": {
        "FlublokPI": {
          "document": "FlublokPI",
          "agents_run": [
            {
              "agent": "supporting_evidence",
              "success": true,
              "timestamp": "2025-07-28T17:41:51.876555"
            }
          ],
          "final_judgment": null,
          "success": true
        }
      },
      "completed_at": "2025-07-28T17:41:51.876564"
    },
    "claim_005": {
      "claim_id": "claim_005",
      "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "started_at": "2025-07-28T17:41:51.876605",
      "documents": {
        "FlublokPI": {
          "document": "FlublokPI",
          "agents_run": [
            {
              "agent": "supporting_evidence",
              "success": true,
              "timestamp": "2025-07-28T17:41:58.217514"
            }
          ],
          "final_judgment": null,
          "success": true
        }
      },
      "completed_at": "2025-07-28T17:41:58.217525"
    },
    "claim_006": {
      "claim_id": "claim_006",
      "claim": "Flublok is produced using a novel production platform in which recombinant HA is expressed in insect cells using a baculovirus expression vector system (BEVS).",
      "started_at": "2025-07-28T17:41:58.217570",
      "documents": {
        "FlublokPI": {
          "document": "FlublokPI",
          "agents_run": [
            {
              "agent": "supporting_evidence",
              "success": true,
              "timestamp": "2025-07-28T17:42:15.518159"
            }
          ],
          "final_judgment": null,
          "success": true
        }
      },
      "completed_at": "2025-07-28T17:42:15.518166"
    },
    "claim_007": {
      "claim_id": "claim_007",
      "claim": "Recombinant HA antigens produced using BEVS have been shown to induce significantly higher levels of broadly cross-reactive antibodies against highly conserved regions of HA compared with egg-derived vaccines.",
      "started_at": "2025-07-28T17:42:15.518205",
      "documents": {
        "FlublokPI": {
          "document": "FlublokPI",
          "agents_run": [
            {
              "agent": "supporting_evidence",
              "success": true,
              "timestamp": "2025-07-28T17:42:27.090197"
            }
          ],
          "final_judgment": null,
          "success": true
        }
      },
      "completed_at": "2025-07-28T17:42:27.090207"
    },
    "claim_008": {
      "claim_id": "claim_008",
      "claim": "Flublok contains 45 micrograms (mcg) of HA per strain vs 15 mcg of HA per strain in a standard-dose influenza vaccine.",
      "started_at": "2025-07-28T17:42:27.090255",
      "documents": {
        "FlublokPI": {
          "document": "FlublokPI",
          "agents_run": [
            {
              "agent": "supporting_evidence",
              "success": true,
              "timestamp": "2025-07-28T17:42:33.117191"
            }
          ],
          "final_judgment": null,
          "success": true
        }
      },
      "completed_at": "2025-07-28T17:42:33.117199"
    }
  },
  "summary": {
    "total_claim_document_pairs": 9,
    "successfully_processed": 9,
    "processing_rate": 1.0,
    "judgment_distribution": {
      "strongly_supported": 0,
      "supported": 0,
      "weakly_supported": 0,
      "unsupported": 0
    }
  }
}